Fundamental research on the development of treatment for triple negative breast cancer
| Project/Area Number |
20591561
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
KUREBAYASHI Junichi Kawasaki Medical School, 医学部, 准教授 (10248255)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORIYA Takuya 川崎医科大学, 医学部, 教授 (00230160)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 乳癌 / トリプルネガティブサブタイプ / Src / エトポシド / 癌幹細胞 / トリプルネガティブ / ダサチニブ / BRCA1 |
|---|
| Research Abstract |
Expression levels of estrogen receptor, progesterone receptor and HER2 in breast cancer tissues have been routinely measured in clinics to predict responses to endocrine therapy and anti-HER2 therapy. Breast tumors expressing none of these three receptors are named as triple negative breast cancer (TNBC). TNBC responds to neither endocrine therapy nor anti-HER2 therapy, is biologically aggressive, tends to recur earlier, and renders a poor prognosis. These findings prompt us to develop new treatment strategies against TNBC. First, we investigated a protein expression profile of various genes related to TNBC characteristics in a panel of human breast cancer cell lines. Next, we studied antitumor activity, effects on cell cycle progression, apoptosis and cancer stem cell population induced by DNA-damaging cytotoxic agents and molecular targeting agents in the panel of breast cancer cell lines. These experimental results have revealed that a Src signal inhibitor, dasatinib and a DNA-damaging agent, etoposide show potent antitumor effect on breast cancer cells of basal B subtype associated with G1-S blockade and induction of apoptosis for dasatinib or G2/M retardation and induction of apoptosis for etoposide, respectively. It is indicated for the first time that dasatinib reduces a proportion of putative cancer stem cells. We also investigated clinical significance of activation of Src signaling using immunohistochemistry in patients with breast cancer. The results of this study have indicated that activation of Src signaling may increase metastatic potential of breast cancer cells.
|
Report
(4 results)
Research Products
(55 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article]2009
Author(s)
紅林淳一
-
Journal Title
みんなに役立つ乳癌の基礎と臨床(医薬ジャーナル社)
Pages: 167-173
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
